Asahi Kasei‘s Sonanos: Revolutionizing Injectable drug Formulation with Next-generation Excipients
Are you a pharmaceutical developer facing challenges with drug solubility, sustained release, or delivering complex biologics? The landscape of injectable drug formulation is constantly evolving, demanding innovative solutions. Asahi Kasei is stepping up to meet this demand with expansions to its Sonanos excipient portfolio, offering a potential breakthrough for a wide range of therapies.
Addressing Formulation Hurdles with Sonanos
Sence its introduction, Sonanos has emerged as a next-generation excipient designed to overcome critical formulation and delivery obstacles. These challenges are notably acute in the development of biologics, peptides, and cutting-edge oncology treatments. Asahi Kasei has been actively collaborating with leading pharmaceutical companies – completing over 60 feasibility studies since 2020 – to refine and expand the capabilities of this innovative platform.
But what is an excipient, and why is innovation in this area so crucial? Excipients are inactive substances formulated alongside the active pharmaceutical ingredient (API) of a medication. They play a vital role in drug delivery, stability, and overall efficacy. Choosing the right excipient can be the difference between a prosperous drug and one that fails to reach its full potential.
Introducing Sonanos PG & Sonanos DS: Targeted Solutions
Asahi Kasei recently unveiled two new specialty grades within the Sonanos family:
* Sonanos PG: Specifically engineered for the sustained release of biologics and peptides. This translates to less frequent dosing, improved patient compliance, and potentially enhanced therapeutic outcomes. imagine a peptide therapy for diabetes requiring weekly instead of daily injections – that’s the kind of impact Sonanos PG aims to deliver.
* Sonanos DS: Formulated to dramatically improve the solubility of poorly water-soluble APIs. Approximately 40% of new drug candidates are poorly soluble, hindering their absorption and bioavailability.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374050/ sonanos DS offers a potential solution to unlock the therapeutic potential of these compounds.
Both new grades represent a meaningful advancement, achieved thru meticulous optimization of encapsulation capacity and overall formulation performance. this isn’t simply about adding a new ingredient; it’s about engineering a solution at the molecular level.
The Science Behind Sonanos: A Deep Dive
Sonanos utilizes a unique polymeric micelle technology. These microscopic structures encapsulate the API, protecting it from degradation and enhancing its delivery to target tissues. This encapsulation offers several key benefits:
* Enhanced solubility: Micelles can solubilize hydrophobic drugs,increasing their bioavailability.
* Sustained Release: The polymeric structure allows for controlled drug release over extended periods.
* Improved Stability: Protection from enzymatic degradation and other environmental factors.
* Reduced Toxicity: Targeted delivery minimizes off-target effects.
This technology aligns with the growing trend towards personalized medicine and targeted drug delivery systems. A recent report by Grand View Research projects the global targeted drug delivery market to reach $89.6 billion by 2030, growing at a CAGR of 7.4% from 2023. https://www.grandviewresearch.com/industry-analysis/targeted-drug-delivery-market
Beyond Formulation: Sonanos in Cancer Vaccine Development
Asahi Kasei’s commitment to Sonanos extends beyond conventional drug formulation. Through its spin-out company, DiveRadGel, the company is actively developing cancer vaccines utilizing a vaccine-grade version of Sonanos, known as Sonanos DV.
Sonanos DV has already entered Good Manufacturing Practice (GMP) production, paving the way for early clinical trials. This demonstrates the versatility of the platform and its potential to address unmet needs in immunotherapy. The use of excipients in vaccine development is gaining traction, with researchers exploring novel materials to enhance immune response and vaccine efficacy.
Practical Implications for Pharmaceutical developers
What does this mean for you, the pharmaceutical developer?
* Explore Feasibility Studies: Asahi Kasei offers samples and collaborative feasibility studies to assess the suitability of Sonanos for your specific formulation challenges.
* Consider Early-Stage Integration: Incorporating Sonanos early in the development process can streamline formulation and reduce potential roadblocks
Keep reading